Gan & Lee Pharmaceuticals Gets Clinical Trial Approval For Atopic Dermatitis Drug

MT Newswires Live2025-12-09

Gan & Lee Pharmaceuticals (SHA:603087) has secured approval from China's National Medical Products Administration to carry out clinical trials for its investigational drug, GLR1044 injection, according to a Shanghai Stock Exchange filing on Tuesday.

The drug is indicated to treat moderate to severe atopic dermatitis in adults who have inadequate control with, or are not suitable for, topical prescription drugs.

GLR1044 injection is a biosimilar of Dupilumab, a drug currently marketed in China only by the original manufacturer, Sanofi, under the brand name Dapoxetine, the company said.

Global sales of Dapoxetine reached 13 billion euros in 2024, Gan & Lee noted, citing data from Sanofi.

The company has spent 66 million yuan in GLR1044's research and development as of Sept. 30.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590604983?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-09 09:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590604983","market":"sh","top_or_hot":-1,"title":"Gan & Lee Pharmaceuticals Gets Clinical Trial Approval For Atopic Dermatitis Drug","media":"MT Newswires Live","content":"<html><body><p> Gan &amp; Lee Pharmaceuticals (SHA:603087) has secured approval from China's National Medical Products Administration to carry out clinical trials for its investigational drug, GLR1044 injection, according to a Shanghai Stock Exchange filing on Tuesday.</p><p>The drug is indicated to treat moderate to severe atopic dermatitis in adults who have inadequate control with, or are not suitable for, topical prescription drugs.</p><p>GLR1044 injection is a biosimilar of Dupilumab, a drug currently marketed in China only by the original manufacturer, <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>, under the brand name Dapoxetine, the company said.</p><p>Global sales of Dapoxetine reached 13 billion euros in 2024, Gan &amp; Lee noted, citing data from <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a>.</p><p>The company has spent 66 million yuan in GLR1044's research and development as of Sept. 30.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gan & Lee Pharmaceuticals Gets Clinical Trial Approval For Atopic Dermatitis Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGan & Lee Pharmaceuticals Gets Clinical Trial Approval For Atopic Dermatitis Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-09 09:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Gan &amp; Lee Pharmaceuticals (SHA:603087) has secured approval from China's National Medical Products Administration to carry out clinical trials for its investigational drug, GLR1044 injection, according to a Shanghai Stock Exchange filing on Tuesday.</p><p>The drug is indicated to treat moderate to severe atopic dermatitis in adults who have inadequate control with, or are not suitable for, topical prescription drugs.</p><p>GLR1044 injection is a biosimilar of Dupilumab, a drug currently marketed in China only by the original manufacturer, <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>, under the brand name Dapoxetine, the company said.</p><p>Global sales of Dapoxetine reached 13 billion euros in 2024, Gan &amp; Lee noted, citing data from <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a>.</p><p>The company has spent 66 million yuan in GLR1044's research and development as of Sept. 30.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"603087","symbol_name":"甘李药业","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2590604983","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590604983","pubTimestamp":1765243081,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Gan & Lee Pharmaceuticals  has secured approval from China's National Medical Products Administration to carry out clinical trials for its investigational drug, GLR1044 injection, according to a Shanghai Stock Exchange filing on Tuesday.The drug is indicated to treat moderate to severe atopic dermatitis in adults who have inadequate control with, or are not suitable for, topical prescription drugs.GLR1044 injection is a biosimilar of Dupilumab, a drug currently marketed in China only by the original manufacturer, Sanofi, under the brand name Dapoxetine, the company said.Global sales of Dapoxetine reached 13 billion euros in 2024, Gan & Lee noted, citing data from Sanofi.The company has spent 66 million yuan in GLR1044's research and development as of Sept. 30.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"603087":"甘李药业","BK0239":"医药制造"},"translate_title":"甘李药业特应性皮炎药物获临床试验批件","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603087":0.9},"content_text":"Gan & Lee Pharmaceuticals (SHA:603087) has secured approval from China's National Medical Products Administration to carry out clinical trials for its investigational drug, GLR1044 injection, according to a Shanghai Stock Exchange filing on Tuesday.The drug is indicated to treat moderate to severe atopic dermatitis in adults who have inadequate control with, or are not suitable for, topical prescription drugs.GLR1044 injection is a biosimilar of Dupilumab, a drug currently marketed in China only by the original manufacturer, Sanofi, under the brand name Dapoxetine, the company said.Global sales of Dapoxetine reached 13 billion euros in 2024, Gan & Lee noted, citing data from Sanofi.The company has spent 66 million yuan in GLR1044's research and development as of Sept. 30.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590604983","isCrawlerRequest":true}